Abbonarsi

Clinical decision support for familial hypercholesterolemia (CDS-FH): Rationale and design of a cluster randomized trial in primary care - 05/04/22

Doi : 10.1016/j.ahj.2022.02.005 
Olof Persson Lindell, MD a, b, , , Lars O Karlsson, MD PhD a, b, , Staffan Nilsson, MD PhD b, c, Emmanouil Charitakis, MD PhD a, b, Emil Hagström, MD PhD d, e, Thomas Muhr, MD a, Lennart Nilsson, MD PhD b, f, Martin Henriksson, PhD g, Magnus Janzon, MD PhD a, b
a Department of Cardiology, University Hospital, Linköping, Sweden 
b Department of Health, Medicine and Caring Sciences, Linköping University, Linköping Sweden 
c Division of Primary Health Care, Region Östergötland, Linköping, Sweden 
d Department of Medical Sciences, Uppsala University, Uppsala, Sweden 
e Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden 
f Department of Medicine, County Hospital Ryhov, Jönköping, Sweden 
g Center for Medical Technology Assessment, Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden 

Reprint requests: Olof Persson Lindell MD, Department of Health, Medicine and Caring Sciences, Linköping University and Department of Cardiology, University Hospital, S58185 Linköping, Sweden.Department of HealthMedicine and Caring SciencesLinköping University and Department of Cardiology, University HospitalLinköpingS58185Sweden

Riassunto

Background

: Familial hypercholesterolemia (FH) is an underdiagnosed and undertreated genetic disorder with high risk of premature atherosclerotic cardiovascular disease and death. Clinical decision support (CDS) systems have the potential to aid in the identification and management of patients with FH. Prior studies using computer-based systems to screen patients for FH have shown promising results, but there has been no randomized controlled trial conducted. The aim of the current cluster randomized study is to evaluate if a CDS can increase the identification of FH.

Methods

: We have developed a CDS integrated in the electronic health records that will be activated in patients with elevated cholesterol levels (total cholesterol >8 mmol/L or low-density lipoprotein-cholesterol >5.5 mmol/L, adjusted for age, ongoing lipid lowering therapy and presence of premature coronary artery disease) at increased risk for FH. When activated, the CDS will urge the physician to send an automatically generated referral to the local lipid clinic for further evaluation. To evaluate the effects of the CDS, all primary care clinics will be cluster randomized 1:1 to either CDS intervention or standard care in a Swedish region with almost 500,000 inhabitants. The primary endpoint will be the number of patients diagnosed with FH at 30 months. Resource use and long-term health consequences will be estimated to assess the cost-effectiveness of the intervention.

Conclusion

: Despite increasing awareness of FH, the condition remains underdiagnosed and undertreated. The present study will investigate whether a CDS can increase the number of patients being diagnosed with FH.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


© 2022  The Authors. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 247

P. 132-148 - maggio 2022 Ritorno al numero
Articolo precedente Articolo precedente
  • Edoxaban-based long-term antithrombotic therapy in patients with atrial fibrillation and stable coronary disease: Rationale and design of the randomized EPIC-CAD trial
  • Min Soo Cho, Do-Yoon Kang, Yong-Seog Oh, Chang Hoon Lee, Eue-Keun Choi, Ji Hyun Lee, Chang Hee Kwon, Gyung-Min Park, Hyun Woo Park, Kyoung-Ha Park, Kyoung-Min Park, Jongmin Hwang, Ki-Dong Yoo, Young-Rak Cho, Yoo Ri Kim, Ki Won Hwang, Eun Sun Jin, Pum-Joon Kim, Ki Hun Kim, Duk-Woo Park, Gi-Byoung Nam
| Articolo seguente Articolo seguente
  • Trends of blood pressure control in the U.S. during the COVID-19 pandemic
  • Nishant P. Shah, Robert M. Clare, Karen Chiswell, Ann Marie Navar, Bimal R. Shah, Eric D. Peterson

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.